Doctor reacts to Oprah Winfrey’s comment on ‘thin people’: ‘Obesity rates aren’t rising globally because of willpower'
Dr. Karan Rajan responds to Oprah Winfrey's insights on thin people, highlighting the complex biology behind obesity, beyond just willpower.
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Hosted on MSN14h
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
GLP-1 drugs like Ozempic may have health benefits, but they come with risks
With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...
The Lancet1d
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions
The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...
BioWorld1d
Novo weight-loss data roll out; Veru ‘leans’ in
As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...
Popular Weight Loss Drugs Could Affect Your Behavior: Scientists Conduct Genetic Investigation
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
MM&M1d
Novo Nordisk’s amycretin cuts weight by 22% in early obesity trial
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
Sweeping New Study Confirms Serious Ozempic Side Effects: What A Doctor Wants You To Know
Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...
Allurion Technologies Shares Are Up Today: What's Going On?
Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to conduct a clinical study evaluating the combination of its Allurion Program ...